Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 221   

Articles published

PFE 32.08 +0.03 (0.10%)
price chart
Pfizer Vs. Merck: 4 Reasons One Is The Superior Choice
Merck, as one of the world's largest drug makers, is a staple of millions of high-yield portfolios. However, when you actually look deeper into the fundamentals of the company, it becomes clear that Merck is a far inferior choice to higher-yielding and ...
Here's Why the Best Is Yet to Come for Pfizer Inc.
The company's acquisitions have added more likely winners. Pfizer bought Anacor in 2016, picking up atopic dermatitis drug Eucrisa, which won FDA approval in December.
Pfizer Inc. Q1 Income Advances 0%
( - Pfizer Inc. ( PFE ) released a profit for its first quarter that increased from last year. The company said its bottom line rose to $4.19 billion, or $0.69 per share.
Pfizer: There Is No Upside Without M&A
Thus, in this article, I will focus on a quantitative valuation of the company without taking into account any potential M&A that Pfizer could announce in 2017/2018, which looks unpredictable, to assess if there is any upside in the company, as ...
Target Price ($37.53) for Pfizer Inc. (PFE) now above Open ($32.12) for Wednesday
Pfizer Inc. (PFE) has built up a compelling picture over the last few trading sessions and both traders and analysts are now starting to take a keen look at the stock.
Pfizer Inc.: FDA Advisory Committee Recommends Approval of Pfizer's Proposed ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company's proposed epoetin alfa ...
EOD Risers: Pfizer Inc., The Coca-Cola Co, Travelers Companies Inc
Shares in Pfizer Inc. company symbol: (NYSE:PFE) a research-based global biopharmaceutical company, rose 0.06% or 0.02 points at the end of yesterday's session.
Hope For Cancer Patients After Pfizer Inc (NYSE:PFE) Strikes The Medivation ...
The data from a mid-stage study released on Wednesday has brought about a number of revelations. But most importantly was the revelation that indeed the $14 billion spent by Pfizer Inc (NYSE:PFE) to actually acquire the breast cancer drug wasn't indeed ...
Does Pfizer Inc. (PFE)'s current closing price competes the market?  TopChronicle
Analyst Advice And Earnings Insight: Pfizer Inc. (PFE), EnteroMedics Inc. (ETRM)  Post Analyst
Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, June 9, 2017 at 11:00 a.m.
Pfizer beats
(Reuters) - Pfizer Inc, the largest U.S. drugmaker, reported a bigger-than-expected quarterly profit, helped by higher sales of breast cancer drug Ibrance and pain relief drug Lyrica.
Pfizer Revenue Falls as Drugs Lose Exclusivity -- Update  Fox Business